Could You Be Eligible for a Georgia Januvia Lawsuit?

Georgia Januvia LawsuitJanuvia, also known as sitagliptin, first received U.S. Food and Drug Administration (FDA) approval in October 2006. However, the medication, manufactured and marketed by Merck & Co., has allegedly caused serious and life-threatening complications in type 2 diabetes patients, and plaintiffs across the country are seeking compensation for their injuries.

Have you or someone you love experienced adverse side effects or received a cancer diagnosis while taking Januvia? You may be entitled to file a Georgia Januvia lawsuit and seek compensation for your injuries. Contact an experienced attorney to learn more about your legal rights.

What is Januvia?

Incretin mimetics mimic the action of incretin within the body, stimulating the pancreas to produce more insulin in type 2 diabetes patients. However, clinical trials suggest that Januvia and other medications may prevent the body from fighting off potential deadly cancers.

Those who are filing Januvia lawsuits against the manufacturer allege that Merck failed to conduct the necessary studies as required by the FDA to evaluate the safety of its medication. Plaintiffs claim that, had Merck acted more efficiently in a reasonable amount of time, many would have had prior warning of the possible risks and chosen an alternate medication instead. Instead, by ignoring the advice and requirement by the FDA, Merck did not have advance warning about the potentially dangerous side effects prior to the drug’s release.

Side Effects of Januvia

Common side effects of Januvia as reported by patients and healthcare providers include:

  • Nausea
  • Sore throat
  • Back, muscle, stomach and joint pain
  • Diarrhea
  • Headaches
  • Stuffy or runny nose
  • Constipation

However, plaintiffs throughout the U.S. are currently filing lawsuits, alleging that Januvia caused other adverse side effects and life-threatening complications. You may be entitled to file your own Georgia Januvia lawsuit if you have experienced one or more of the following conditions:

  • Loss of appetite
  • Difficulty urinating
  • Vomiting
  • Increased heart rate
  • Nausea
  • Shortness of breath
  • Swelling
  • Allergic reactions
  • Upper abdominal pain

Due to the increasing number of adverse event reports submitted to the FDA, the agency announced in March 2013 that it would be conducting its own investigation of Januvia and other incretin mimetics to determine whether there is a potential link between the medications and acute pancreatitis or other pre-cancerous cell changes.

Current Januvia Lawsuits

A federal proceeding involving incretin mimetics such as Januvia, Janumet, Byetta and Victoza determined that pending lawsuits should be consolidated into a multidistrict litigation (MDL) in the Southern District of California. After this decision was made, an additional 60 claims were filed from plaintiffs seeking compensation from the drugs’ manufacturers for their alleged injuries.

According to claims, the manufacturers failed to warn the public and healthcare providers about the potential dangers and risks associated with the medications. Plaintiffs allege that these incretin mimetics caused pancreatitis, thyroid cancer, pancreatic cancer and other health complications. If you feel you have a claim, contact an attorney to learn more about filing your Georgia Januvia lawsuit.

Considering a Georgia Januvia Lawsuit? Contact Us Today

If you or a loved one have suffered from complications or injuries while taking Januvia, you may be entitled to file a Georgia Januvia lawsuit and seek compensation. At the Georgia Injury Attorney Group, we will do our best to answer your questions and help you to determine if you have a valid claim. We will connect you with an experienced attorney who will handle your Georgia Januvia lawsuit in an effort to help you seek the compensation to which you may be entitled. The statute of limitations varies from state to state, so to help your chance of recovering damages, contact us today for more information.

 

Comments